Nov 18- StemCells Inc said its experimental stem cell therapy improved the functioning and strength of limbs in patients with spinal cord injuries, becoming the second company to report promising data on the treatment for such injuries. StemCells' research centers around the treatment for spinal cord injuries, visual problems that begin at the retina and...» Read More
Halftime's hottest trades today: 6 trades in 50 seconds. Exploring social media rallies, biotech's reversal, earnings season, Peabody Energy, and JP Morgan.
As gene therapy emerges in the biotech industry and Phil Nadeau, Cowen and Company Biotechnology Analyst, explains why it could be the next billion dollar industry.
The CEO of biotech company Genfit told CNBC that the markets are overreacting to the results of its NASH study.
After a tough week for biotech stocks, David Seaburg of Cowen & Co. and Craig Johnson of Piper Jaffray call the next move.
CNBC's Meg Tirrell reports on the recent drop in biotechs and whether it is a threat to the overall market.
CNBC contributor Barbara Ryan of Clermont Partners, discusses whether biotech is a good place to be right now, and how investors
Eric Schmidt, Cowen & Co. biotech analyst, thinks biotech will continue to be a great business and will move higher. Insight, with Geoff Porges, Sanford Bernstein.
A new antibiotic-resistant "superbug" may have contributed to the deaths of 2 patients at Ronald Reagan-UCLA Medical Center. What companies may be on track to combat the deadly virus, with CNBC's Meg Tirrell.
New DNA evidence says significant chunks of humanity may carry genes from a few powerful men, including Genghis Khan.
Caterpillar and 3Ms' poor earnings performance "spooked investors", however tech and healthcare are expected to save the earnings season, says Christine Short, senior vice president at Estimize.
Biotech stocks in the U.S. have outperformed significantly over the last three years -- and this can continue, says Matthew Roden, executive director of biotechnology equity research at UBS AG.
Biopharma executives at the J.P. Morgan Healthcare Conference talk about this year's biggest challenges.
Sam Waksal, former Imclone Systems CEO, reveals how the ImClone scandal has impacted his life.
CNBC's Meg Tirrell, and Sam Waksal, Kadmon founder & chairman, discusses his role in the company.
CNBC's Meg Tirrell, and Sam Waksal, Kadmon founder & chairman, discuss plans to take the biotech company public.
Dr. George Scangos, Biogen Idec CEO, discusses new therapies in multiple sclerosis, Alzheimer's disease and pain.
Anne Wojcicki, co-founder and CEO of genetic-testing startup 23andMe, discusses the new deals with Pfizer and Genentech.
CNBC's Meg Tirrell speaks to Robert Hugin, Celgene chairman & CEO, about the company's ambitious long-term guidance and broad-based drug pipeline.
CNBC's Meg Tirrell speaks to John Lechleiter, Eli Lilly CEO, about the strength and outlook for the health care sector, and what new drugs he's most excited about.
CNBC's Meg Tirrell provides insight to the debate over transparency from biotech companies. Biotech investor Brad Loncar, thinks this is just an awareness issue.